Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Intervention Indication Therapeutic Area Year Actions
Nivolumab in addition to radiation therapy for glioblastoma – first line Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation Glioma Neurological Cancer 2018 View  |  Download
Nivolumab in addition to temozolomide and radiotherapy for MGMT-methylated glioblastoma in newly diagnosed adults - first line Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation , Temozolomide (Temodar; Temodal; SCH 52365) Glioma Neurological Cancer 2019 View  |  Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation Melphalan hydrochloride (Cydex; CDX-353; Phelinun) Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer 2021 View  |  Download
Selumetinib for treating symptomatic, inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in adults Selumetinib (AZD6244; ARRY-142886) Plexiform neurofibromas Neurological Cancer , Neurology 2023 View  |  Download
Toca 511 and Toca FC for Recurrent High Grade Glioma Toca-511 (vocimagene amiretrorepvec) , Toca-FC (flucytosine) Glioma Neurological Cancer 2018 View  |  Download
Vorasidenib for treating residual or recurrent grade 2 glioma Vorasidenib Glioma Neurological Cancer 2023 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications